Acadia Pharmaceuticals | ACAD - Selling And Administration Expenses


Acadia Pharmaceuticals reported $160.79M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Corcept Therapeutics USD 156.9M 28.85M Jun/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Eisai JPY 114.83B 4.71B Jun/2026
Eli Lilly USD 2.93B 198M Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
J&J USD 6.42B 381M Jun/2026
Moderna USD 216M 43M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Pfizer USD 2.92B 1.16B Mar/2026
Prothena USD 12.67M 5.02M Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026